Everything below concerns Preclinical study. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
The closure temperature or blocking temperature represents the temperature below which the mineral is a closed system for the studied isotopes. If a material that selectively rejects the daughter nuclide is heated above this temperature, any daughter nuclides that have been accumulated over time will be lost through diffusion, resetting the isotopic "clock" to zero. As the mineral cools, the crystal structure begins to form and diffusion of isotopes is less easy. At a certain temperature, the crystal structure has formed sufficiently to prevent diffusion of isotopes. Thus an igneous or metamorphic rock or melt, which is slowly cooling, does not begin to exhibit measurable radioactive decay until it cools below the closure temperature. The age that can be calculated by radiometric dating is thus the time at which the rock or mineral cooled to closure temperature. This temperature varies for every mineral and isotopic system, so a system can be closed for one mineral but open for another. Dating of different minerals and/or isotope systems (with differing closure temperatures) within the same rock can therefore enable the tracking of the thermal history of the rock in question with time, and thus the history of metamorphic events may become known in detail. These temperatures are experimentally determined in the lab by artificially resetting sample minerals using a high-temperature furnace. This field is known as thermochronology or thermochronometry.
=== Use in drug-induced neutropenia === Neutropenia can be a severe side effect of clozapine, an antipsychotic medication in the treatment of schizophrenia. G-CSF can restore neutrophil count. Following a return to baseline after stopping the drug, it may sometimes be safely rechallenged with the added use of G-CSF.
=== Eruption of the fighting === 27 December 1918: The uprising starts in the evening with shooting in front of Poznań's police headquarters. Fighting also start in other towns: Szamotuły, Środa Wielkopolska, Pniewy, Opalenica, Buk, Trzemeszno, Września and Gniezno are captured. Poles in Poznań capture the main train station, the main post office and part of city fortifications. 28 December 1918: The Poles in Poznań capture Cytadela (a main stronghold), Fort Grolmann and an armory on ul. Wielkie Garbary The commission of the NRL promotes Captain Stanisław Taczak to temporary commander-in-chief of the uprising (he is also promoted to rank of major). 29 December 1918: The Poles capture Grodzisk Wielkopolski, Kłecko, Kórnik, Wielichowo, Gostyń, Witkowo and other towns. 30 December 1918 Failure of peace talks between the insurgents and the German authorities, the latter refusing to take the responsibility for the hostilities of 27 December. In Poznań, the Poles force the German 6th Regiment of Grenadiers from their barracks. After talks, the regiment leaves the city with their weapons. The Poles capture Wronki, Wągrowiec, Gołańcz. Polish soldiers stop a German offensive against Gniezno near Zdziechowa. 31 December 1918 The Poles capture Kościan, Oborniki Wielkopolskie, Ostrów Wielkopolski. A unit of Poles under command of Paweł Cyms begins offensive on Cuiavia. 1 January 1919 Paderewski leaves Poznań. The capture of Jarocin, Krotoszyn and Mogilno.
The waves were focused (by curving the antenna) and refracted (by a prism-shaped graphene bilayer because the conductivity in the two-atom-thick prism is larger than in the surrounding one-atom-thick layer.) The plasmonic metal-graphene nanoantenna was composed by inserting a few nanometers of oxide between a dipole gold nanorod and the monolayer graphene. The used oxide layer here can reduce the quantum tunneling effect between graphene and metal antenna. With tuning the chemical potential of the graphene layer through field effect transistor architecture, the in-phase and out-phase mode coupling between graphene plasmonics and metal plasmonics is realized. The tunable properties of the plasmonic metal-graphene nanoantenna can be switched on and off via modifying the electrostatic gate-voltage on graphene.
Crustacean cardioactive peptide (CCAP) is a highly conserved, amidated cyclic nonapeptide with the primary structure PFCNAFTGC-NH2 (ProPheCysAsnAlaPheThrGlyCys-NH2) and a disulfide bridge between Cys3 and Cys9. It is found in crustaceans and insects where it behaves as a cardioaccelerator, neuropeptide transmitter for other areas of the nervous system and a hormone. CCAP was first isolated from the pericardial organs of the shore crab Carcinus maenas, where it has a role in regulating heartbeat. It was assumed that this was the peptide's main function and its name reflects this.
Sources: en.wikipedia.org
Plag, Ingo "Word-Formation in English", Cambridge University Press, 2003, ISBN à0521525632, 9780521525633 Rider, Nic G.; Caso, Taymy J.; Czech, Spencer; Karasic, Dan H. (2022). "Terminology in Transgender Medicine". In van Trotsenburg, Mick; Luikenaar, Rixt A. C.; Meriggiola, Maria Cristina (eds.). Context, Principles and Practice of TransGynecology: Managing Transgender Patients in ObGyn Practice. Cambridge UP. doi:10.1017/9781108899987. ISBN 978-1-108-89998-7. Ragosta, Sachiko; Obedin-Maliver, Juno; Fix, Laura; Stoeffler, Ari; Hastings, Jen; Capriotti, Matthew R.; Flentje, Annesa; Lubensky, Micah E.; Lunn, Mitchell R.; Moseson, Heidi (1 September 2021). "From 'Shark-Week' to 'Mangina': An Analysis of Words Used by People of Marginalized Sexual Orientations and/or Gender Identities to Replace Common Sexual and Reproductive Health Terms". Health Equity. 5 (1). Mary Ann Liebert: 707–717. doi:10.1089/heq.2021.0022. PMC 8665782. PMID 34909540. This article incorporates text from this free content work. Licensed under CC-BY 4.0. Rajalingam R (2012). "Overview of the Killer Cell Immunoglobulin-Like Receptor System". Immunogenetics. Methods in Molecular Biology. Vol. 882. pp. 391–414. doi:10.1007/978-1-61779-842-9_23. ISBN 978-1-61779-841-2. PMID 22665247. Saladin, Kenneth S. (2010). Anatomy & Physiology The Unity of Form and Function (5th ed.). McGraw Hill. ISBN 978-0077361358. Simpson, John A.; Weiner, Edmung (1989). The Oxford English Dictionary. Oxford: Clarendon Press. ISBN 9780198611868. Sompayrac L (2019). How the immune system works. Hoboken, NJ: Wiley-Blackwell.
=== Anions and cations === Cations including sodium, potassium, calcium, and magnesium are common in industrial water supplies. Common anions include chloride, sulfate, and bicarbonate. Several methods are used to remove ions from input water supplies including reverse osmosis, distillation, and/or ion exchange. Distillation can be used to remove non-volatile metal cations and was historically used for water purification. However, distillation is energy-intensive compared to the combination of reverse osmosis and ion exchange which are more common in modern systems.
== Home media == Dredd was released on DVD, Blu-ray and Digital Download on 8 January 2013 in North America, and 14 January in the UK. The Blu-ray edition contains the 2D and 3D versions of the film and a digital copy. The DVD and Blu-ray editions contain seven featurettes: "Mega-City Masters: 35 Years of Judge Dredd", "Day of Chaos: The Visual Effects of Dredd 3D", "Dredd", "Dredd's Gear", "The 3rd Dimension", "Welcome to Peachtrees", and a "Dredd Motion Comic Prequel" narrated by Urban. During its first week on sale in the UK, Dredd was the number 1 selling DVD and Blu-ray. During the week of its release in North America, it was the number 1 selling DVD and Blu-ray with approximately 650,000 units sold, and Blu-ray units accounting for nearly 50% of that figure. It was also the best-selling digital download for that period. Sales spiked in the United Kingdom in June 2013, following a reported rumour that it could influence DNA Films' decision to pursue a sequel. By September 2013, Dredd was estimated to have earned approximately $10 million in home media sales in North America, while in the UK it marked over 270 days in online-retailer Amazon's top 100 selling home media. By July 2017, this sales figure was estimated to have increased to $20 million.
=== Mass spectrometry === Previously, many studies used Mass Spectrometry (MS) in different fragmentation modes to detect AMPylated peptides. In responses to the distinctive fragmentation techniques, AMPylated protein sequences disintegrated at different parts of AMP. While electron transfer dissociation (ETD) creates minimum fragments and less complicated spectra, collision-induced dissociation (CID) and high-energy collision (HCD) fragmentation generate characteristic ions suitable for AMPylated proteins identification by generating multiple AMP fragments. Due to AMP's stability, peptide fragmentation spectra is easy to read manually or with search engines.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.